Garbe C - Search Results

1

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.

Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F. Sinnberg T, et al. Among authors: garbe c. J Invest Dermatol. 2009 Jun;129(6):1500-15. doi: 10.1038/jid.2008.379. Epub 2008 Dec 11. J Invest Dermatol. 2009. PMID: 19078992 Free article.

2

Detection of dermcidin-derived peptides in sweat by ProteinChip technology.

Flad T, Bogumil R, Tolson J, Schittek B, Garbe C, Deeg M, Mueller CA, Kalbacher H. Flad T, et al. Among authors: garbe c. J Immunol Methods. 2002 Dec 1;270(1):53-62. doi: 10.1016/s0022-1759(02)00229-6. J Immunol Methods. 2002. PMID: 12379338

3

Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin.

Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL. Murakami M, et al. Among authors: garbe c. J Invest Dermatol. 2002 Nov;119(5):1090-5. doi: 10.1046/j.1523-1747.2002.19507.x. J Invest Dermatol. 2002. PMID: 12445197 Free article.

4

Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.

Garbe C, Paul A, Kohler-Späth H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B, Meier F, Schittek B, Blaheta HJ, Blum A, Rassner G. Garbe C, et al. J Clin Oncol. 2003 Feb 1;21(3):520-9. doi: 10.1200/JCO.2003.01.091. J Clin Oncol. 2003. PMID: 12560444

5

Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.

Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B. Garbe C, et al. Cancer. 2003 Apr 1;97(7):1737-45. doi: 10.1002/cncr.11250. Cancer. 2003. PMID: 12655531 Free article.

6

Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma.

Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Möller H, Maczey E, Rassner G, Herlyn M, Garbe C. Meier F, et al. Among authors: garbe c. Exp Dermatol. 2003 Jun;12(3):296-306. doi: 10.1034/j.1600-0625.2003.120310.x. Exp Dermatol. 2003. PMID: 12823444

7

Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis.

van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, Van Muijen GN, Herlyn M, Bloemers HP, Swart GW. van Kempen LC, et al. Among authors: garbe c. J Invest Dermatol. 2004 May;122(5):1293-301. doi: 10.1111/j.0022-202X.2004.22531.x. J Invest Dermatol. 2004. PMID: 15140234 Free article.

8

The natural course of cutaneous melanoma.

Leiter U, Meier F, Schittek B, Garbe C. Leiter U, et al. Among authors: garbe c. J Surg Oncol. 2004 Jul 1;86(4):172-8. doi: 10.1002/jso.20079. J Surg Oncol. 2004. PMID: 15221923 Review.

9

Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo.

Rieg S, Steffen H, Seeber S, Humeny A, Kalbacher H, Dietz K, Garbe C, Schittek B. Rieg S, et al. Among authors: garbe c. J Immunol. 2005 Jun 15;174(12):8003-10. doi: 10.4049/jimmunol.174.12.8003. J Immunol. 2005. PMID: 15944307

10

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G, Herlyn M. Meier F, et al. Among authors: garbe c. Front Biosci. 2005 Sep 1;10:2986-3001. doi: 10.2741/1755. Front Biosci. 2005. PMID: 15970553 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

800 results

Search Page

Filters